Wikisage, the free encyclopedia of the second generation, is digital heritage
Primidone: Difference between revisions
Jump to navigation
Jump to search
mNo edit summary |
(→Links) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 24: | Line 24: | ||
[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4242891/pdf/11606_2014_Article_2907.pdf Factors Associated with Ordering Laboratory Monitoring of High-Risk Medications] | [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4242891/pdf/11606_2014_Article_2907.pdf Factors Associated with Ordering Laboratory Monitoring of High-Risk Medications] | ||
de Leon, J 2015 [http://www.elsevier.es/en-revista-revista-psiquiatria-salud-mental-486-articulo-the-effects-antiepileptic-inducers-in-S2173505015000175 Efectos de los inductores antiepilépticos en la neuropsicofarmacología: una cuestión ignorada. Parte I: Resumen para los clínicos de la situación actual] | |||
{{Wikidata|Q420383}} | {{Wikidata|Q420383}} | ||
{{refs}} | |||
[[Category:Anticonvulsants]] | |||
Latest revision as of 00:49, 26 August 2017
Primidone is an anticonvulsant that is metabolized to phenylethylmalonamide (PEMA) and phenobarbital[1], historically considered a prodrug of phenobarbital[2], nevertheless it is superior against tremor [3] [4] Chronic high-cumulative doses have shown to increase the fracture risk in a dose-dependent manner
ATC
antiepileptic drugs
Links
Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs
Factors Associated with Ordering Laboratory Monitoring of High-Risk Medications
